Brevinin-1-RAA7 peptide precursor
Need Assistance?
  • US & Canada:
    +
  • UK: +

Brevinin-1-RAA7 peptide precursor

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Brevinin-1-RAA7 peptide precursor is an antimicrobial peptide found in Odorrana andersonii (golden crossband frog). It has antimicrobial activity.

Category
Functional Peptides
Catalog number
BAT-012892
Molecular Formula
C111H189N29O27S2
Molecular Weight
2426.03
IUPAC Name
(4R,7S,10S,13S,16S,19S,22R)-22-((S)-2-((S)-2-((2S,3R)-2-((S)-1-(L-leucyl-L-prolyl-L-alanyl-L-valyl-L-isoleucyl-L-arginyl-L-valyl-L-alanyl-L-alanyl-L-asparaginyl-L-valyl-L-leucyl)pyrrolidine-2-carboxamido)-3-hydroxybutanamido)-3-methylbutanamido)-3-phenylpropanamido)-7,10-bis(4-aminobutyl)-16-((S)-sec-butyl)-13-((R)-1-hydroxyethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosane-4-carboxylic acid
Synonyms
Leu-Pro-Ala-Val-Ile-Arg-Val-Ala-Ala-Asn-Val-Leu-Pro-Thr-Val-Phe-Cys-Ala-Ile-Thr-Lys-Lys-Cys (Disulfide bridge: Cys17-Cys23)
Purity
≥96%
Sequence
LPAVIRVAANVLPTVFCAITKKC (Disulfide bridge: Cys17-Cys23)
Storage
Store at -20°C
1. Enteroglucagon
J J Holst Annu Rev Physiol. 1997;59:257-71. doi: 10.1146/annurev.physiol.59.1.257.
The gene encoding proglucagon, the biosynthetic precursor of glucagon, is expressed not only in the pancreatic islets but also in endocrine cells of the gastrointestinal mucosa. The proglucagon (PG)-derived peptides from the gut include glicentin (corresponding to PG 1-69); smaller amounts of oxyntomodulin (PG 33-69) and glicentin-related pancreatic polypeptide (GRPP, PG 1-30); glucagon-like peptide-1 (GLP-1, PG 78-107 amide); intervening peptide-2 (IP-2, PG 111-122 amide); and glucagon-like peptide-2 (GLP-2, PG 126-158). All are secreted into the blood in response to ingestion of carbohydrates and lipids. Only oxyntomodulin and GLP-1 have proven biological activity; oxyntomodulin possibly because it interacts (but with lower potency) with GLP-1 and glucagon receptors. GLP-1 is the most potent insulinotropic hormone known and functions as an incretin hormone. It also inhibits glucagon secretion and, therefore, lowers blood glucose. This effect is preserved in patients with non-insulin-dependent diabetes mellitus, in whom infusions of GLP-1 may completely normalize blood glucose. However, GLP-1 also potently inhibits gastrointestinal secretion and motility, and its physiological functions include mediation of the "ileal-brake" effect, i.e. the inhibition of upper gastrointestinal functions elicited by the presence of unabsorbed nutrients in the ileum. As such it may serve to regulate food intake.
2. Peptidome: Chaos or Inevitability
Irina Lyapina, Vadim Ivanov, Igor Fesenko Int J Mol Sci. 2021 Dec 4;22(23):13128. doi: 10.3390/ijms222313128.
Thousands of naturally occurring peptides differing in their origin, abundance and possible functions have been identified in the tissue and biological fluids of vertebrates, insects, fungi, plants and bacteria. These peptide pools are referred to as intracellular or extracellular peptidomes, and besides a small proportion of well-characterized peptide hormones and defense peptides, are poorly characterized. However, a growing body of evidence suggests that unknown bioactive peptides are hidden in the peptidomes of different organisms. In this review, we present a comprehensive overview of the mechanisms of generation and properties of peptidomes across different organisms. Based on their origin, we propose three large peptide groups-functional protein "degradome", small open reading frame (smORF)-encoded peptides (smORFome) and specific precursor-derived peptides. The composition of peptide pools identified by mass-spectrometry analysis in human cells, plants, yeast and bacteria is compared and discussed. The functions of different peptide groups, for example the role of the "degradome" in promoting defense signaling, are also considered.
3. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease
Arun K Ghosh, Heather L Osswald Chem Soc Rev. 2014 Oct 7;43(19):6765-813. doi: 10.1039/c3cs60460h.
BACE1 (β-secretase, memapsin 2, Asp2) has emerged as a promising target for the treatment of Alzheimer's disease. BACE1 is an aspartic protease which functions in the first step of the pathway leading to the production and deposition of amyloid-β peptide (Aβ). Its gene deletion showed only mild phenotypes. BACE1 inhibition has direct implications in the Alzheimer's disease pathology without largely affecting viability. However, inhibiting BACE1 selectively in vivo has presented many challenges to medicinal chemists. Since its identification in 2000, inhibitors covering many different structural classes have been designed and developed. These inhibitors can be largely classified as either peptidomimetic or non-peptidic inhibitors. Progress in these fields resulted in inhibitors that contain many targeted drug-like characteristics. In this review, we describe structure-based design strategies and evolution of a wide range of BACE1 inhibitors including compounds that have been shown to reduce brain Aβ, rescue the cognitive decline in transgenic AD mice and inhibitor drug candidates that are currently in clinical trials.
Online Inquiry
Verification code
Inquiry Basket